Skip to content
Review

Abstract 6326: Dose-Response Efficacy and Safety of the Aldosterone Synthase Inhibitor Baxdrostat in Resistant Hypertension: A Systematic Review and Network Meta-Analysis

Nov 2026 · Circulation · 0 citations

Abstract

Background: Resistant hypertension (RH) is associated with increased cardiovascular morbidity and mortality, with limited treatment options due to adverse effects and suboptimal control. Aldosterone plays a central role in RH pathophysiology, making aldosterone synthase inhibition a promising therapeutic target. Baxdrostat, a selective CYP11B2 inhibitor, has demonstrated dose-dependent reductions in aldosterone and blood pressure. This study aimed to evaluate the efficacy and safety of baxdrostat across different doses in patients with RH. Research Question: Does braxdostat show a dose-dependent reduction in the SBP and DBP of patients with RH? Methods: This systematic review and network meta-analysis was conducted in accordance with the PRISMA-NMA guidelines and was prospectively registered with PROSPERO (CRD420261359149). A comprehensive search of PubMed, Cochrane CENTRAL, Embase, Scopus, and Web of Science was performed from inception to April 2026. Randomized, double-blind, placebo-controlled trials in adults with RH were included. A frequentist random-effects network meta-analysis using a graph-theoretical approach was performed to compare baxdrostat doses (0.5-2 mg), with treatment ranking based on P-scores. Heterogeneity and inconsistency were assessed using I 2 , τ 2 , and Q statistics. Results: Four randomized controlled trials comprising 1535 RH patients were included in our analysis. Baxdrostat demonstrated a dose-dependent reduction in seated systolic blood pressure (SBP), with significant decreases at 2 mg (mean difference [MD] –8.46 mmHg, 95% CI –12.00 to –4.92) and 1 mg (–5.89 mmHg, –9.83 to –1.94), while 0.5 mg was not significantly different from placebo. Reductions in 24 hour ambulatory SBP were consistent across effective doses. Seated diastolic blood pressure (DBP) reduction was significant only at 2 mg. All doses significantly reduced aldosterone levels, however, the highest reduction was seen with braxdostat 2 mg (-4.03, 95% CI: -5.29 to -2.77) for serum aldosterone and -187.40 for urinary aldosterone. This was accompanied by compensatory increases in the urinary renin. Higher doses (1 mg and 2 mg) were associated with an increased risk of overall adverse events (1.21, 95% CI: 1.03 to 1.43, and 1.17, 95% CI: 1.01 to 1.36, respectively), and hyperkalemia (4.51, 95% CI: 1.73 to 11.70); baxdrostat 0.5 mg demonstrated the safest outcomes, however, it ranked first in causing hyponatremia and hypotension. There was no significant increase in serious adverse events compared with placebo. Conclusion: Baxdrostat is an effective and generally well-tolerated therapy for resistant hypertension, demonstrating dose-dependent blood pressure and aldosterone reductions. Its upstream mechanism offers a novel alternative to mineralocorticoid receptor antagonists. Larger and long-term studies are warranted to confirm its clinical role.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.